Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14706856 | 0.89 | PIK3CD (0.45) | PIK3CDHRH3SMN1; SMN2CYP2D6GNAI3 | |
| SCHEMBL22318587 | 0.88 | PIK3CD (0.42) | PIK3CDHRH3SMN1; SMN2CYP2D6GNAI3 | |
| SCHEMBL22013047 | 0.84 | PIK3CD (0.52) | PIK3CDHRH3SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL22300882 | 0.84 | PIK3CD (0.52) | PIK3CDHRH3SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL7907337 | 0.84 | PIK3CD (0.52) | PIK3CDHRH3SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL14328666 | 0.84 | PIK3CD (0.52) | PIK3CDHRH3SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL24940791 | 0.83 | PIK3CD (0.42) | PIK3CDHRH3SMN1; SMN2CYP2D6GNAI3 | |
| SCHEMBL22790838 | 0.83 | HRH3 (0.39) | PIK3CDHRH3SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL24755017 | 0.83 | GNAI3 (0.48) | PIK3CDHRH3SMN1; SMN2CYP2D6GNAI3 | |
| SCHEMBL23134534 | 0.82 | HRH3 (0.48) | PIK3CDHRH3SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | EGFR, ABL1, ERBB2 | PIK3CD 44/4885HRH3 801/4885SMN1; SMN2 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.